Pyruvate and Metabolic Flexibility: Illuminating a Path Toward Selective Cancer Therapies

Trends in Biochemical Sciences

Volumn 41, Issue 3, 2016, Pages 219-230

  Olson, Kristofor A ^a   Schell, John C ^a   Rutter, Jared ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer; Metabolic flexibility; Metabolic heterogeneity; Metabolism; Pyruvate; Stem cells

Indexed keywords

ADENOSINE TRIPHOSPHATE; CISPLATIN; DICHLOROACETIC ACID; GLUTAMATE DEHYDROGENASE; GLUTAMINASE; HYPOXIA INDUCIBLE FACTOR; LACTATE DEHYDROGENASE; MONOCARBOXYLATE TRANSPORTER; PLATINUM COMPLEX; PYRUVATE DEHYDROGENASE; PYRUVATE KINASE; PYRUVIC ACID;

ADJUVANT THERAPY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; CANCER CELL; CANCER THERAPY; CARCINOGENESIS; CELL METABOLISM; CITRIC ACID CYCLE; FATTY ACID OXIDATION; GENE MUTATION; GLYCOLYSIS; HUMAN; HYPOXIA; METABOLIC DISORDER; METASTASIS; MITOCHONDRIAL RESPIRATION; NEOPLASM; OXIDATIVE PHOSPHORYLATION; OXYGEN CONSUMPTION; PRIORITY JOURNAL; REVIEW; SOLID TUMOR; STEM CELL; TUMOR GROWTH; METABOLISM; NEOPLASMS; OXIDATION REDUCTION REACTION;

GLYCOLYSIS; HUMANS; NEOPLASMS; OXIDATION-REDUCTION; PYRUVIC ACID;

EID: 84959467603     PISSN: 09680004     EISSN: 13624326     Source Type: Journal    
DOI: 10.1016/j.tibs.2016.01.002     Document Type: Review

References (103)

1. Azzi A. In memory of Donald Nicholson. IUBMB Life 2012, 648:659-660.
2. Petersen K.F., et al. Effect of aging on muscle mitochondrial substrate utilization in humans. Proc. Natl. Acad. Sci. U.S.A. 2015, 112:11330-11334.
3. Takubo K., et al. Regulation of glycolysis by Pdk functions as a metabolic checkpoint for cell cycle quiescence in hematopoietic stem cells. Cell Stem Cell 2013, 12:49-61.
4. Yu W-M., et al. Metabolic regulation by the mitochondrial phosphatase PTPMT1 is required for hematopoietic stem cell differentiation. Cell Stem Cell 2013, 12:62-74.
5. Vacanti N.M., et al. Regulation of substrate utilization by the mitochondrial pyruvate carrier. Mol. Cell 2014, 56:425-435.
6. Gray L.R., et al. Hepatic mitochondrial pyruvate carrier 1 is required for efficient regulation of gluconeogenesis and whole-body glucose homeostasis. Cell Metab. 2015, 22:669-681.
7. McCommis K.S., et al. Loss of mitochondrial pyruvate carrier 2 in the liver leads to defects in gluconeogenesis and compensation via pyruvate-alanine cycling. Cell Metab. 2015, 22:682-694.
8. Bishop S.P., Altschuld R.A. Increased glycolytic metabolism in cardiac hypertrophy and congestive failure. Am. J. Physiol. 1970, 218:153-159.
9. Breckenridge R.A., et al. Hypoxic regulation of hand1 controls the fetal-neonatal switch in cardiac metabolism. PLoS Biol. 2013, 11:e1001666.
10. Goodwin G.W., et al. Improved energy homeostasis of the heart in the metabolic state of exercise. Am. J. Physiol. Heart Circ. Physiol. 2000, 279:H1490-H1501.
11. Masoud W.G.T., et al. Failing mouse hearts utilize energy inefficiently and benefit from improved coupling of glycolysis and glucose oxidation. Cardiovasc. Res. 2014, 101:30-38.
12. Melenovsky V., et al. Availability of energetic substrates and exercise performance in heart failure with or without diabetes. Eur. J. Heart Fail. 2012, 14:754-763.
13. Ussher J.R., et al. Stimulation of glucose oxidation protects against acute myocardial infarction and reperfusion injury. Cardiovasc. Res. 2012, 94:359-369.
14. Doenst T., et al. Cardiac metabolism in heart failure: implications beyond ATP production. Circ. Res. 2013, 113:709-724.
15. Martínez-Zamora A., et al. Defective expression of the mitochondrial-tRNA modifying enzyme GTPBP3 triggers AMPK-mediated adaptive responses involving complex i assembly factors, uncoupling protein 2, and the mitochondrial pyruvate carrier. PLoS ONE 2015, 10:e0144273.
16. Fernandez-Caggiano M., et al. Analysis of mitochondrial proteins in the surviving myocardium after ischemia identifies mitochondrial pyruvate carrier expression as possible mediator of tissue viability. Mol. Cell Proteomics 2016, 15:246-255.
17. Goulston A. A note on the beneficial effect of the ingestion of cane sugar in certain forms of heart disease. BMJ 1911, 1:615.
18. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
19. Bardella C., et al. SDH mutations in cancer. Biochim. Biophys. Acta 2011, 1807:1432-1443.
20. King A., et al. Succinate dehydrogenase and fumarate hydratase: linking mitochondrial dysfunction and cancer. Oncogene 2006, 25:4675-4682.
21. Rutter J., et al. Succinate dehydrogenase - assembly, regulation and role in human disease. Mitochondrion 2010, 10:393-401.
22. Warburg O., et al. The metabolism of tumors in the body. J. Gen. Physiol. 1927, 8:519-530.
23. Halestrap A.P., Wilson M.C. The monocarboxylate transporter family - role and regulation. IUBMB Life 2012, 64:109-119.
24. Halestrap A.P. The monocarboxylate transporter family - structure and functional characterization. IUBMB Life 2012, 64:1-9.
25. Boroughs L.K., DeBerardinis R.J. Metabolic pathways promoting cancer cell survival and growth. Nat. Cell Biol. 2015, 17:351-359.
26. DeNicola G.M., Cantley L.C. Cancer's fuel choice: new flavors for a picky eater. Mol. Cell 2015, 60:514-523.
27. Li Z., et al. The multifaceted regulation and functions of PKM2 in tumor progression. Biochim. Biophys. Acta 2014, 1846:285-296.
28. Desai S., et al. Tissue-specific isoform switch and DNA hypomethylation of the pyruvate kinase PKM gene in human cancers. Oncotarget 2013, 5:8202-8210.
29. Christofk H.R., et al. Pyruvate kinase M2 is a phosphotyrosine-binding protein. Nature 2008, 452:181-186.
30. Christofk H.R., et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 2008, 452:230-233.
31. Bettaieb A., et al. Protein tyrosine phosphatase 1B regulates pyruvate kinase M2 tyrosine phosphorylation. J. Biol. Chem. 2013, 288:17360-17371.
32. Anastasiou D., et al. Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis. Nat. Chem. Biol. 2012, 8:839-847.
33. Lunt S.Y., et al. Pyruvate kinase isoform expression alters nucleotide synthesis to impact cell proliferation. Mol. Cell 2015, 57:95-107.
34. Birsoy K., et al. An essential role of the mitochondrial electron transport chain in cell proliferation is to enable aspartate synthesis. Cell 2015, 162:540-551.
35. Sullivan L.B., et al. Supporting aspartate biosynthesis is an essential function of respiration in proliferating cells. Cell 2015, 162:552-563.
36. Miao P., et al. Lactate dehydrogenase a in cancer: a promising target for diagnosis and therapy. IUBMB Life 2013, 65:904-910.
37. Le A., et al. Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:2037-2042.
38. Fantin V.R., et al. Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell 2006, 9:425-434.
39. Xie H., et al. Targeting lactate dehydrogenase-A inhibits tumorigenesis and tumor progression in mouse models of lung cancer and impacts tumor-initiating cells. Cell Metab. 2014, 19:795-809.
40. Sheng S.L., et al. Knockdown of lactate dehydrogenase A suppresses tumor growth and metastasis of human hepatocellular carcinoma. FEBS J. 2012, 279:3898-3910.
41. Wang J., et al. Lactate dehydrogenase A negatively regulated by miRNAs promotes aerobic glycolysis and is increased in colorectal cancer. Oncotarget 2015, 6:19456-19468.
42. Zhu J., et al. Monocarboxylate transporter 4 facilitates cell proliferation and migration and is associated with poor prognosis in oral squamous cell carcinoma patients. PLoS ONE 2014, 9:e87904.
43. Witkiewicz A.K., et al. Using the 'reverse Warburg effect' to identify high-risk breast cancer patients: stromal MCT4 predicts poor clinical outcome in triple-negative breast cancers. Cell Cycle 2012, 11:1108-1117.
44. Nakayama Y. Prognostic significance of monocarboxylate transporter 4 expression in patients with colorectal cancer. Exp. Ther. Med. 2012, 3:25-30.
45. Baek G., et al. MCT4 defines a glycolytic subtype of pancreatic cancer with poor prognosis and unique metabolic dependencies. Cell Rep. 2014, 9:2233-2249.
46. Hao J., et al. Co-expression of CD147 (EMMPRIN), CD44v3-10, MDR1 and monocarboxylate transporters is associated with prostate cancer drug resistance and progression. Br. J. Cancer 2010, 103:1008-1018.
47. Herzig S., et al. Identification and functional expression of the mitochondrial pyruvate carrier. Science 2012, 337:93-96.
48. Bricker D.K., et al. A mitochondrial pyruvate carrier required for pyruvate uptake in yeast, Drosophila, and humans. Science 2012, 337:96-100.
49. Schell J.C., et al. A role for the mitochondrial pyruvate carrier as a repressor of the Warburg effect and colon cancer cell growth. Mol. Cell 2014, 56:400-413.
50. Liang L., et al. Sirt3 binds to and deacetylates mitochondrial pyruvate carrier 1 to enhance its activity. Biochem. Biophys. Res. Commun. 2015, 468:807-812.
51. Kaplon J., et al. A key role for mitochondrial gatekeeper pyruvate dehydrogenase in oncogene-induced senescence. Nature 2013, 498:109-112.
52. Fujiwara S., et al. PDK1 inhibition is a novel therapeutic target in multiple myeloma. Br. J. Cancer 2013, 108:170-178.
53. Hitosugi T., et al. Tyrosine phosphorylation of mitochondrial pyruvate dehydrogenase kinase 1 is important for cancer metabolism. Mol. Cell 2011, 44:864-877.
54. Comerford S.A., et al. Acetate dependence of tumors. Cell 2014, 159:1591-1602.
55. Schug Z.T., et al. Acetyl-CoA synthetase 2 promotes acetate utilization and maintains cancer cell growth under metabolic stress. Cancer Cell 2015, 27:57-71.
56. Mashimo T., et al. Acetate is a bioenergetic substrate for human glioblastoma and brain metastases. Cell 2014, 159:1603-1614.
57. Stacpoole P.W., Felts J.M. Diisopropylammonium dichloroacetate (DIPA) and sodium dichloracetate (DCA): effect on glucose and fat metabolism in normal and diabetic tissue. Metab. Clin. Exp. 1970, 19:71-78.
58. Whitehouse S., et al. Mechanism of activation of pyruvate dehydrogenase by dichloroacetate and other halogenated carboxylic acids. Biochem. J. 1974, 141:761-774.
59. + channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell 2007, 11:37-51.
60. Strum S.B., et al. Case report: sodium dichloroacetate (DCA) inhibition of the 'Warburg effect' in a human cancer patient: complete response in non-Hodgkin's lymphoma after disease progression with rituximab-CHOP. J. Bioenerg. Biomembr. 2012, 45:307-315.
61. Olszewski U., et al. In vitro cytotoxicity of combinations of dichloroacetate with anticancer platinum compounds. Clin. Pharmacol. 2010, 2:177-183.
62. Garon E.B., et al. Dichloroacetate should be considered with platinum-based chemotherapy in hypoxic tumors rather than as a single agent in advanced non-small cell lung cancer. J. Cancer Res. Clin. Oncol. 2014, 140:443-452.
63. Roh J-L., et al. Activation of mitochondrial oxidation by PDK2 inhibition reverses cisplatin resistance in head and neck cancer. Cancer Lett. 2015.
64. De Preter G., et al. Inhibition of the pentose phosphate pathway by dichloroacetate unravels a missing link between aerobic glycolysis and cancer cell proliferation. Oncotarget 2015, 5. Published online November 2, 2015. 10.18632/oncotarget.6272.
65. Delaney L.M., et al. Dichloroacetate affects proliferation but not survival of human colorectal cancer cells. Apoptosis 2015, 20:63-74.
66. Ho N., Coomber B.L. Pyruvate dehydrogenase kinase expression and metabolic changes following dichloroacetate exposure in anoxic human colorectal cancer cells. Exp. Cell Res. 2015, 331:73-81.
67. Shahrzad S., et al. Sodium dichloroacetate (DCA) reduces apoptosis in colorectal tumor hypoxia. Cancer Lett. 2010, 297:75-83.
68. Feuerecker B., et al. DCA promotes progression of neuroblastoma tumors in nude mice. Am. J. Cancer Res. 2015, 5:812-820.
69. Tibiletti M.G., et al. Physical map of the D6S149-D6S193 region on chromosome 6Q27 and its involvement in benign surface epithelial ovarian tumours. Oncogene 1998, 16:1639-1642.
70. Yang C., et al. Glutamine oxidation maintains the TCA cycle and cell survival during impaired mitochondrial pyruvate transport. Mol. Cell 2014, 56:414-424.
71. Marusyk A., Polyak K. Tumor heterogeneity: causes and consequences. Biochim. Biophys. Acta 2010, 1805:105-117.
72. Pribluda A., et al. Intratumoral heterogeneity: from diversity comes resistance. Clin. Cancer Res. 2015, 21:2916-2923.
73. Abelson S., et al. Intratumoral heterogeneity in the self-renewal and tumorigenic differentiation of ovarian cancer. Stem Cells 2012, 30:415-424.
74. Son S.H., et al. Prognostic implication of intratumoral metabolic heterogeneity in invasive ductal carcinoma of the breast. BMC Cancer 2014, 14:585.
75. Sonveaux P., et al. Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J. Clin. Invest. 2008, 118:3930-3942.
76. McGillen J.B., et al. Glucose-lactate metabolic cooperation in cancer: insights from a spatial mathematical model and implications for targeted therapy. J. Theor. Biol. 2014, 361:190-203.
77. Martinez-Outschoorn U.E., et al. Catabolic cancer-associated fibroblasts transfer energy and biomass to anabolic cancer cells, fueling tumor growth. Semin. Cancer Biol. 2014, 25:47-60.
78. Fiaschi T., et al. Reciprocal metabolic reprogramming through lactate shuttle coordinately influences tumor-stroma interplay. Cancer Res. 2012, 72:5130-5140.
79. LeBleu V.S., et al. PGC-1α mediates mitochondrial biogenesis and oxidative phosphorylation in cancer cells to promote metastasis. Nat. Cell Biol. 2014, 16:992-1003.
80. Hamabe A., et al. Role of pyruvate kinase M2 in transcriptional regulation leading to epithelial-mesenchymal transition. Proc. Natl. Acad. Sci. U.S.A. 2014, 111:15526-15531.
81. Ito K., Suda T. Metabolic requirements for the maintenance of self-renewing stem cells. Nat. Rev. Mol. Cell Biol. 2014, 15:243-256.
82. Suda T., et al. Metabolic regulation of hematopoietic stem cells in the hypoxic niche. Cell Stem Cell 2011, 9:298-310.
83. Ushio-Fukai M., Rehman J. Redox and metabolic regulation of stem/progenitor cells and their niche. Antioxid. Redox Signal. 2014, 21:1587-1590.
84. Rodrigues A.S., et al. Differentiate or die: 3-bromopyruvate and pluripotency in mouse embryonic stem cells. PLoS ONE 2015, 10:e0135617.
85. Dang C.V. MYC, metabolism, cell growth, and tumorigenesis. Cold Spring Harb. Perspect. Med. 2013, 3:1-15.
86. Wilson A., et al. c-Myc controls the balance between hematopoietic stem cell self-renewal and differentiation. Genes Dev. 2004, 18:2747-2763.
87. Varlakhanova N.V., et al. Myc maintains embryonic stem cell pluripotency and self-renewal. Differentiation 2010, 80:9-19.
88. Maxwell P.H., et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999, 399:271-275.
89. Bruick R.K., McKnight S.L. A conserved family of prolyl-4-hydroxylases that modify HIF. Science 2001, 294:1337-1340.
90. Chen C., et al. Regulation of glut1 mRNA by hypoxia-inducible factor-1. Interaction between H-ras and hypoxia. J. Biol. Chem. 2001, 276:9519-9525.
91. Gleadle J.M., Ratcliffe P.J. Induction of hypoxia-inducible factor-1, erythropoietin, vascular endothelial growth factor, and glucose transporter-1 by hypoxia: evidence against a regulatory role for Src kinase. Blood 1997, 89:503-509.
92. Mathupala S.P., et al. Glucose catabolism in cancer cells: identification and characterization of a marked activation response of the type II hexokinase gene to hypoxic conditions. J. Biol. Chem. 2001, 276:43407-43412.
93. 2 homeostasis by hypoxia-inducible factor 1 alpha. Genes Dev. 1998, 12:149-162.
94. Semenza G.L., et al. Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1. J. Biol. Chem. 1996, 271:32529-32537.
95. Ullah M.S., et al. The plasma membrane lactate transporter MCT4, but not MCT1, is up-regulated by hypoxia through a HIF-1alpha-dependent mechanism. J. Biol. Chem. 2006, 281:9030-9037.
96. Rosafio K., Pellerin L. Oxygen tension controls the expression of the monocarboxylate transporter MCT4 in cultured mouse cortical astrocytes via a hypoxia-inducible factor-1α-mediated transcriptional regulation. Glia 2014, 62:477-490.
97. Kim J-W., et al. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab. 2006, 3:177-185.
98. Papandreou I., et al. HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metab. 2006, 3:187-197.
99. Denko N.C. Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nat. Rev. Cancer 2008, 8:705-713.
100. Keith B., et al. HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression. Nat. Rev. Cancer 2012, 12:9-22.
101. Semenza G.L. HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations. J. Clin. Invest. 2013, 123:3664-3671.
102. Denko N.C. Hypoxic regulation of metabolism offers new opportunities for anticancer therapy. Expert Rev. Anticancer Ther. 2014, 14:979-981.
103. Masoud G.N., Li W. HIF-1α pathway: role, regulation and intervention for cancer therapy. Acta Pharm. Sin. B 2015, 5:378-389.